BFRIW
Biofrontera Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$0.00
+0.00%Oct 8, 2026, 13:22 UTC
Biofrontera Inc. submitted a supplemental new drug application to the FDA seeking to expand Ameluz red-light photodynamic therapy labeling to actinic keratoses on the full body, covering treatment fields of up to approximately 240 cm² with an adjusted illumination protocol.
Source:Sep 14, 2026, 13:26 UTC
Biofrontera announced that the FDA approved its Ameluz red-light photodynamic therapy for the treatment of superficial basal cell carcinoma.
Aug 13, 2026, 12:51 UTC
Biofrontera Inc. reported its financial results for the second quarter of 2026, highlighting a 33% revenue growth.